Table 1 Tumor Characteristics and immune status in stage II-III colon carcinoma patient.

From: Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II–III colorectal cancer

Clinicopathological parameters

Total no.

CD8+ TILs

p value

Total no.

Tumor CD274/PD-L1

p value

High

Low

High

Low

 

867

283 (33%)

584 (67%)

 

864

384 (44%)

480 (56%)

 

Sex

   

0.39

   

0.7

  Female

401 (46%)

125 (44%)

276 (47%)

 

401 (46%)

181 (47%)

220 (46%)

 

  Male

466 (54%)

158 (56%)

308 (53%)

 

463 (54%)

203 (53%)

260 (54%)

 

  Age

   

0.16

   

0.59

  <65

387 (45%)

136 (48%)

251 (43%)

 

385 (45%)

175 (46%)

210 (44%)

 

  ≥65

480 (55%)

147 (52%)

333 (57%)

 

479 (55%)

209 (54%)

270 (56%)

 

Tumor location

   

0.02

   

0.68

  Proximal colon

425 (49%)

155 (55%)

270 (46%)

 

423 (49%)

185 (48%)

238 (50%)

 

  Distal colon

442 (51%)

128 (45%)

314 (54%)

 

441 (51%)

199 (52%)

242 (50%)

 

pT stage

   

<0.0001*

   

0.001*

  Tis

2 (0.2%)

1 (0.4%)

1 (0.2%)

 

2 (0.2%)

1 (0.3%)

1 (0.2%)

 

  pT1

3 (0.4%)

0 (0%)

3 (0.5%)

 

3 (0.4%)

2 (0.5%)

1 (0.2%)

 

  pT2

29 (3%)

15 (5%)

14 (2%)

 

29 (3%)

15 (4%)

14 (3%)

 

  pT3

701 (81%)

239 (84%)

462 (79%)

 

698 (81%)

311 (81%)

387 (81%)

 

  pT4

132 (15%)

28 (10%)

104 (18%)

 

132(15%)

55 (14%)

77 (16%)

 

pN stage

   

<0.0001*

   

0.85

  Negative

457 (53%)

176 (62%)

281 (48%)

 

456 (53%)

204 (53%)

252 (53%)

 

  Positive

410 (47%)

107 (38%)

303 (52%)

 

408 (47%)

180 (47%)

228 (48%)

 

pathological TNM stage

   

<0.0001*

   

0.85

  Stage II

457 (53%)

176 (62%)

281 (48%)

 

456 (53%)

204 (53%)

252 (53%)

 

  Stage III

410 (47%)

107 (38%)

303 (52%)

 

408 (47%)

180 (47%)

228 (48%)

 

Tumor differentiation

   

<0.0001*

   

0.02

  Well to moderate

734 (85%)

217 (77%)

517 (89%)

 

732 (85%)

313 (82%)

419 (87%)

 

  Poor

121 (14%)

63 (22%)

58 (10%)

 

120 (14%)

65 (17%)

55 (11%)

 

  Unknown

12 (1%)

3 (1%)

9 (2%)

 

12 (1%)

6 (2%)

6 (1%)

 

Lymphovascular invasion (LVI)

   

0.3103

   

0.3034

  Absent

421 (49%)

144 (51%)

277 (47%)

 

419 (48%)

194 (51%)

225 (47%)

 

  Present

441(50%)

137 (48%)

304 (52%)

 

440 (51%)

188 (49%)

252 (52%)

 

  Unknown

5 (1%)

2 (1%)

3 (1%)

 

5 (1%)

2 (1%)

3(1%)

 

Perineural Invasion (PNI)

   

<0.0001*

   

0.0195

  Absent

534 (62%)

203 (72%)

331 (57%)

 

533 (62%)

221 (57%)

312 (65%)

 

  Present

326 (%)

78 (27%)

248 (42%)

 

324 (37%)

161 (42%)

163 (34%)

 

  Unknown

7 (1%)

2 (1%)

5 (1%)

 

7 (1%)

2 (1%)

5 (1%)

 

MMR status

   

<0.0001*

   

0.14

  MMR-proficient

795 (92%)

245 (87%)

550 (94%)

 

794 (92%)

347 (90%)

447 (93%)

 

  MMR-deficient

68 (8%)

38 (13%)

30 (5%)

 

68 (8%)

36 (9%)

32 (7%)

 

  NA

4 (0%)

0 (0%)

4 (1%)

 

2 (0.2%)

1 (0.3%)

1 (0.2%)

 
  1. NA: not available. Fisher’s exact test was used when >25% of the cells have expected counts less than 5. The Pearson’s chi-square and Fisher’s exact test did not include the “NA” and “unknown” group. *p < 0.005 is significant and 0.005 < p < 0.05 is suggestive evidence.
Back to article page